tiprankstipranks
Analyst Profile
Followed by 18 other investors
.
Uy Ear

Uy Ear

Mizuho Securities
Wall Street Analyst
Ranked #1,736 out of 8,047 Analysts on TipRanks (#3,141 out of 21,521 overall experts)

Success Rate

70%
23 out of 33 Profitable Transactions

Average Return

15.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Uy Ear's ratings since 2019 and opened each position for the duration of 1 Year:
69.70% of your transactions would have been profitable with an average return of 15.0%

Stock Rating Distribution

56Ratings
89.29% Buy
10.71% Hold
0.00% Sell
Distribution of Uy Ear's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Arcutis Biotherapeutics Inc
(ARQT)
Rating Type:Buy
Dates:Feb 02, 2022 - Jan 01, 1970
Gain:69.10%
The most profitable rating made by Uy Ear

Uy Ear's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Teva Pharmaceutical
Hold
Initiated
$14.00
(24.89% Upside)
0.00%
1
Ironwood Pharma
Hold
Initiated
$14.00
(19.15% Upside)
0.00%
1
Portola Pharma
Hold
Initiated
0.00%
1
uniQure
Buy
Assigned
$52.00
(155.15% Upside)
67%
+8.47%
6
Sarepta Therapeutics
Buy
Reiterated
$160.00
(46.79% Upside)
100%
+40.20%
3
Alkermes
Buy
Reiterated
$34.00
(30.02% Upside)
0%
-6.00%
1
Evolus
Buy
Reiterated
$15.00
(56.25% Upside)
0%
-11.10%
1
Arcutis Biotherapeutics
Buy
Reiterated
$57.00
(126.82% Upside)
83%
+29.93%
24
Selecta Biosciences
Buy
Reiterated
$8.00
(225.20% Upside)
67%
+21.37%
3
Neurocrine
Hold
Reiterated
$98.00
(-7.22% Downside)
0.00%
1
List of latest recommendations made by Uy Ear. Click to expand and see Uy Ear's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More